ReviewAnnals of surgical oncology2020
The Landmark Series: Gallbladder Cancer.
Review in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Body composition as a prognostic factor in cholangiocarcinoma: a meta-analysis.Nutrition journal · 2024Pooled it
- Diagnosis and treatment of gallbladder and gastric multiple primary malignancies.Journal of pancreatology · 2026Article
- Gallbladder Cancer Incidentally Found at Cholecystectomy: Perioperative Risk Factors.Journal of gastrointestinal cancer · 2024Article
- Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.Cancer science · 2024Article
- Post-operative morbidity after neoadjuvant chemotherapy and resection for gallbladder cancer: A national surgical quality improvement program analysis.World journal of gastrointestinal surgery · 2024Article
- New trends in diagnosis and management of gallbladder carcinoma.World journal of gastrointestinal oncology · 2024Review
- Non-coding RNAs as potential biomarkers of gallbladder cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Adenosquamous carcinoma of the gallbladder: a rare entity and dilemmas in its management.BMJ case reports · 2023Article
- Multiparameter diagnostic model based onBMC cancer · 2023Article
- NLRP3 inflammasome-induced pyroptosis in digestive system tumors.Frontiers in immunology · 2023Review
- HSV: The scout and assault for digestive system tumors.Frontiers in molecular biosciences · 2023Review
- Surgery in combination with systemic chemotherapy is associated with improved survival in stage IV gallbladder cancer.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2022Article
- Combined hepatocellular carcinoma-cholangiocarcinoma in a patient with Fontan-associated liver disease.BMJ case reports · 2022Article
- Article
- Gallbladder cancer.Nature reviews. Disease primers · 2022Review
- Carcinosarcoma with chondroid differentiation and neuroendocrine carcinoma: unusual triphasic tumour arising from intracholecystic papillary neoplasm of the gall bladder.BMJ case reports · 2022Article
- Age-specific clinicopathological characteristics and prognostic analysis of neuroendocrine carcinomas of the gallbladder.Cancer medicine · 2022Article
- Perioperative Versus Adjuvant Chemotherapy in the Management of Incidentally Found Gallbladder Cancer (OPT-IN).Annals of surgical oncology · 2022Article
- Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers.Frontiers in pharmacology · 2022Article
- Gallbladder cancer: Historical treatment and new management options.World journal of gastrointestinal oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the rarity of gallbladder carcinoma, level I evidence to guide the multimodal treatment of this disease is lacking. Since 2010, four randomized phase III clinical trials including ABC-02, PRODIGE-12/ACCORD-18, BILCAP, and BCAT, and a single-arm phase II trial (SWOG0809) have been reported on the use of adjuvant strategies for biliary malignancies. These trials have led to the recommendation that patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy and those with R1 margins could be considered for chemoradiotherapy. Because there is no level I evidence to guide neoadjuvant therapy or surgical management, current consensus is based on strong retrospective data. The following review summarizes available trials and highlights the best available evidence that form the basis of consensus statements for the multimodal management of gallbladder carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.